Icahn and Khan make for odd bedfellows

NEW YORK, April 3 (Reuters Breakingviews) – Deals can create strange bedfellows. Case in point is Illumina (ILMN.O), which on Monday was ordered by the Federal Trade Commission, led by Chair Lina Khan, to unwind its $7 billion acquisition of Grail (GRAL.O). This puts Khan on the same side as Carl Icahn, who wants Illumina to ditch the deal for seemingly opposite reasons. Illumina makes DNA sequencing machines used in medical research. It discovered by accident it could detect cancer by finding tumor fragments in blood. It set up Grail to develop tests, but has had trouble deciding whether having…